Summary of questionnaire responses
| QUESTION | NUMBER OF RESPONSES (TOTAL=45) | |||
| Number of unique nurse responses (from individual centres) | 45 | UK | 10 | |
| USA | 9 | |||
| Netherlands | 6 | |||
| Canada | 5 | |||
| New Zealand | 4 | |||
| Ireland | 2 | |||
| Sweden | 2 | |||
| Australia, Croatia, Denmark, Finland, Germany, Romania, Switzerland | 1 each | |||
| NUMBER OF RESPONSES | % OF RESPONSES | |||
| Ever switched clotting factor product? | 45 | Yes | 43 | 95% |
| No | 2 | 5% | ||
| Reason(s) for switch (more than one answer possible) | 33* | Clinical need | 34 | |
| Funder/purchaser changed product | 30 | |||
| Patient request/preference | 21 | |||
| Was switch protocol-based? | 40* | Yes | 20 | 50% |
| No | 20 | 50% | ||
| If so, who wrote the protocol? | 24* | Haemophilia team | 15 | 62.5% |
| Nurse/nurse specialist | 4 | 16.5% | ||
| Doctors | 5 | 21% | ||
| Frequency of blood tests for pharmacokinetics before switch | 26* | Don’t know | 1 | 4% |
| No prior testing | 6 | 23% | ||
| Blood testing at least once | 18 | 69% | ||
| Depends on product | 1 | 4% | ||
| Frequency of blood tests for pharmacokinetics after switch** | 25* | None | 4 | 16% |
| Depends on product | 4 | 16% | ||
| Depends on clinical need | 1 | 4% | ||
| No/inappropriate response | 16 | 64% | ||
| Screen for inhibitors before switch? | 43* | Yes | 37 | 86% |
| No | 6 | 14% | ||
| Was patient association involved? | 43* | Yes | 11 | 26% |
| No | 27 | 63% | ||
| Not sure | 5 | 11% | ||